Since Roche launched its long-acting eye disease medicine Vabysmo in 2022, Bayer and Regeneron have seen the impact on sales of their rival treatment Eylea, with the U.S. biotech taking a bigger hit.

Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the drug an advantage over rival Roche’s Vabysmo (faricimab). A ...

As regulatory delays continue to plague Regeneron’s efforts to develop Eylea, sales for the eye disease medicine remain in decline. | As regulatory delays continue to plague Regeneron's Eylea ...

We were pleased with Regeneron's performance to start 2026, highlighted by strong commercial execution across our key growth products, continued pipeline progress, a disciplined approach to capital ...

Regeneron Pharmaceuticals Inc. asked a federal judge to require Amgen Inc. to turn over damages evidence for antitrust counterclaims accusing Regeneron of using patents for its blockbuster Eylea drug ...

Regeneron Pharmaceuticals, Inc. REGN recently announced that its supplemental biologics license application (sBLA) for the ophthalmology drug, Eylea (aflibercept), has been accepted by the FDA for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. Few drugs become multi-billion blockbusters, but those that do usually have similar characteristics. They treat big, and growing ...

NEW YORK (AP) -- Shares of Regeneron Pharmaceuticals rose Monday, briefly hitting an all-time high, after the company reported new details from studies of its drug Eylea as a treatment for diabetic ...

Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year. Few drugs become multi-billion blockbusters, but those that do ...